Recently, our studies indicated that lovastatin inhibits the proliferation of cholangiocarcinoma cells via inhibition of the expression of transforming growth factor (TGF)-β1, cyclooxygenase (COX)-2, and intercellular adhesion molecule (ICAM)-1 [4]. Here, TGFB1 is linked to cholangiocarcinoma.